January 19, 2017 News by Patricia Silva, PhD Reports on MS Treatment Market Show Growing Shift to Oral Therapies The multiple sclerosis (MS) market shiftedĀ during 2016, with oral disease-modifying therapies (DMTs) capturing a greater share and Sanofi-Genzyme’s Aubagio (teriflunomide) being poised for growth, according to a press releaseĀ fromĀ Spherix Global Insights. The conclusions were included in the company’sĀ āRealTime Dynamix: Multiple Sclerosis,ā a quarterly report based…
January 18, 2017 News by Patricia Silva, PhD Majority of Irish Physicians Approve of Cannabis as MS Treatment, Survey Finds Most Irish general practitioners (GPs) are against decriminalizing cannabis use, but many, especially those over age 50, sayĀ it canĀ be useful for treating multiple sclerosis (MS) and other medical conditions, according to a recent survey. The results are detailed in the study, “Irish general practitioner attitudes toward decriminalisation…
January 4, 2017 News by Joana Fernandes, PhD Survey Assesses How Health Professionals Treat Other Health Conditions in MS Patients Healthcare providers frequently assess multiple sclerosis (MS) patients for the development of other health conditions, such as depression, anxiety, pain and sleep disturbance, according to results of a survey-study. The study also includes information about how health professionals treat and counsel MS patients diagnosed with these conditions. The study, ā…
November 14, 2016 News by Joana Fernandes, PhD Effectiveness and Safety of DMDs Top Patient Concerns with These Therapies, Survey Says In general, patients with multiple sclerosis (MS) choose their disease-modifying drug (DMD) treatment based on considerations of effectiveness and potential sideĀ effects. But the weight they assign to these considerations can differ widely, making it important they are part of treatment decisions, especially regarding DMDs. TheseĀ findingsĀ are in the report,Ā āIdentification and…
June 3, 2016 News by Patricia Silva, PhD #CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information PeopleĀ with primary progressive multiple sclerosis (PPMS)Ā are usually older and more disabled than thoseĀ withĀ relapsing-remitting MS, researchers atĀ Washington UniversityĀ reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in theĀ NARCOMSĀ registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, ā…
May 26, 2016 News by Patricia Silva, PhD Sanofi Genzyme Launches vs.MS Global Campaign to Raise Awareness on MS’ Physical and Emotional Burden Sanofi GenzymeĀ recently launched vs.MS, a global initiative to raise awareness of the often unspoken physical and emotional burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. OnĀ World MS DayĀ yesterday, the company called onĀ the MS community to learn more about the…
April 7, 2016 News by Patricia Silva, PhD MS Patients Asked to Take Part in Survey of Risk/Benefit Considerations in Choosing Treatments The National Multiple Sclerosis Society is funding a new survey to understand how people living with multiple sclerosis (MS) weigh risks against benefits when choosing MS therapies. The survey was developed by Dr. Robert Fox, a neurologist, working with colleagues at the Cleveland Clinic and the MS patient…
March 28, 2016 News by Patricia Silva, PhD MS Survey Reviews How Patients Perceive Diet, Exercise and Drug Treatments A survey, summarizing the views of 2,600 multiple sclerosis (MS) patients, showed how people manage their disease in real life ā and the results offer some surprising insights that might provide clues for future treatment development and optimization. Conducted by aĀ Stanford University-trained geneticist, Dr. Yael Wilnai, results from the…
March 15, 2016 News by Margarida Azevedo, MSc New MS Survey Looks into Patients’ Appraisal of Risks, Benefits When Choosing Therapies A large-scale online survey, funded by the National Multiple Sclerosis Society Ā and developed by researchers,Ā is investigating how multiple sclerosis (MS) patients perceive and evaluate the risks and benefits of available therapies. InvestigatorsĀ encourage MS patients to participate in the survey, titled āMultiple Sclerosis Risk Tolerance,ā which can be…
February 25, 2016 News by Margarida Azevedo, MSc Biogen’s ‘1MSg Campaign’ Encourages MS Patients to Better Manage Their Disease, Engage with Specialists BiogenĀ is launching an initiative developed with the assistance of clinical experts ā the 1MSg campaignĀ āĀ to educate and encourage multiple sclerosis (MS) patients to make disease management decisions that are well-informed andĀ basedĀ onĀ the latest scientific research. The campaignās motto is āTake control, known your choices,ā and one of its main…
November 23, 2015 News by Patricia Silva, PhD MS Society Supports 2 Projects Advancing MS Care, Services The United Kingdom basedĀ Multiple Sclerosis Society (MS Society) recently announced Ā£1.98 million in grants toĀ new MS research projects in different disease-related areas. A panel of experts carefully selected 16 projects to be funded through the MS Societyās 2015 grant round, totaling Ā£1,979,879. All selected projects fulfill the requirements of…